Tocagen and ApolloBio Enter License Agreement to Develop and Commercialize Toca 511 and Toca FC in the Greater China Region

Tocagen eligible to receive up to $127 million in upfront payment, development and commercial milestones, plus additional double-digit tiered sales royalties Upfront and near-term development milestones payments total up to $20 million SAN DIEGO and ... Biopharmaceuticals, Oncology, Licensing Tocagen, ApolloBio, immunotherapy, high grade glioma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news

Related Links:

aro Historically restrained to immune defense against parasite infections, allergic inflammation has been recently rediscovered to protect from a wide array of environmental triggers, such as xenobiotics and carcinogens, which can induce DNA damage and ultimately lead to cancer development. Moreover, cells and mediators typical of allergic responses can importantly modulate the tissue inflammatory milieu, which represents a crucial gatekeeper towards the acquisition of malignancy by cancer cells through immune escape. Numerous studies have described an inverse association between allergies and glioma development. Mast ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
CONCLUSIONS: Our findings suggest that disruption of IL-6 signaling in GBM reduces local and systemic myeloid-driven immunosuppression and enhances immune-mediated anti-tumor responses against GBM. PMID: 30824583 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Publication date: August 2019Source: Current Opinion in Behavioral Sciences, Volume 28Author(s): Sebastian Otto-Meyer, Jan Lumibao, Eugene Kim, Erik Ladomersky, Lijie Zhai, Kristen L Lauing, Denise M Scholtens, Frank Penedo, Christina Amidei, Rimas V Lukas, Derek A WainwrightA malignant brain tumor diagnosis is often accompanied by intense feelings and can be associated with psychosocial conditions including depression, anxiety, and increased distress levels. Previous work has highlighted the impact of uncontrolled psychological distress among brain tumor patients. Given the negative impact of maladaptive psychosocial and ...
Source: Current Opinion in Behavioral Sciences - Category: Psychiatry & Psychology Source Type: research
Source: OncoImmunology - Category: Cancer & Oncology Authors: Source Type: research
ConclusionsGrade IV gliomas have an alteration in both circulating and tumor-associated myeloid cells and, differently from grade II and III gliomas, show a significant presence of blood-derived, immune suppressive macrophages. BMDM and MG have different functional properties.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
Source: OncoImmunology - Category: Cancer & Oncology Authors: Source Type: research
Christopher T. Petersen, Giedre Krenciute
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Human gliomas are highly fatal tumors with a significant feature of immune suppression. The association of the immune system in gliomas is gradually revealed, and immunotherapy is expected to improve the survi...
Source: Journal of Neuroinflammation - Category: Neurology Authors: Tags: Research Source Type: research
Conclusion: The expression of ADAMTSL4 is closely related to the clinicopathologic characteristics of pGBM. Meanwhile, it may play a critical role in immune-related processes. As a secreted glycoprotein, ADAMTSL4 is a promising circulating biomarker for pGBM, deserving further investigations. PMID: 30728876 [PubMed - in process]
Source: Disease Markers - Category: Laboratory Medicine Tags: Dis Markers Source Type: research
Doctors in China may have uncovered an effective second- or third-line treatment option for patients with malignant pleural mesothelioma. Dr. RongQin Meng, an oncologist at 363 Hospital in Cheng Du, said the investigational drug Apatinib (rivoceranib) could become part of a much-needed advance in mesothelioma treatment. After first- and second-line chemotherapy combinations had failed to slow tumor growth in a 58-year-old woman, Apatinib provided a five-month progression-free survival. “I was surprised at the result,” Meng told The Mesothelioma Center at “After taking the drug, the quality o...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
More News: Brain Tumor | Cancer & Oncology | China Health | Glioma | Immunotherapy